Imaging and clinical surveillance results
| Author, Year, Location | Overall Recurrence Rate, Stratified by Surveillance Arm | MPC Detected by Surveillance Arm (if Available) and Site of MPC | Curative-Intent Treatment of Cancers |
|---|---|---|---|
| Leclère et al6 2023, France | Overall 21% (164/782) Clinical 19% (53/285) FDG-PET/CT 22% (111/497) | 51 Total MPC reported FDG-PET/CT detection rate: 10.3% (51/497) FDG-PET/CT detection rate by site: 37% (19/51) Lung24% (12/51) Head and neck8% (4/51) Esophageal31% (16/51) OtherClinical detection rate: not reported | 81.9% (91/111) Subclinical HNSCC recurrences and 90.2% (46/51) MPC treated |
| Chen et al8 2023, US | Overall 15% (51/340) Clinical 12% (19/153) Imaging 17% (32/187) | 68 Total MPC reportedOverall detection rate by site:22% (15/68) Skin cancers 16% (11/68) Lung cancers 13% (9/68) Head and neck 13% (9/68) Genitourinary 9% (6/68) Esophageal or gastric 26% (18/68) Other multiple sites Reported no difference in diagnosis of MPC by cohort, numbers by cohort not specified | No. of HNSCC recurrences or MPCs treated with curative intent not reported |